Evidence map›Paper›PMID 42377824›Full record

ArticleMolecular diversity2026

Design, synthesis and biological evaluations of novel VEGFR-2 inhibitors based on Fruquintinib and Cabozantinib.

Xueyan Ding, Heliang Wei, Mengling Ye, Yudan Huang, Aike Su, Xiaoying Ding, Wenfa Chen, Zhaosheng Tang, Junjie Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xueyan DingSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Heliang WeiSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Mengling YeSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Yudan HuangSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Aike SuSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Xiaoying DingSchool of Medicine, Huaqiao University, Quanzhou, 362000, China.
Wenfa ChenDepartment of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China. 67942074@qq.com.
Zhaosheng TangDepartment of Endocrinology, Shanghai East Hospital, Shanghai, 200120, China.
Junjie MaSchool of Medicine, Huaqiao University, Quanzhou, 362000, China. majunjie3612@hqu.edu.cn.ORCID https://orcid.org/0000-0001-5844-9984

Funding

Natural Science Foundation of Fujian Province 2025J01169Natural Science Foundation of Xiamen Municipality 3502Z202573050Quanzhou High-level Talents Innovation and Entrepreneurship Project 2024QZC005YR
6 · The paper itself

Abstract

In this study, two series of VEGFR-2 inhibitors were designed based on the Fruquintinib and Cabozantinib. Series 1 compounds retained the quinazoline skeleton and amide group of Fruquintinib, while the benzofuran moiety was replaced with a coumarin moiety, and various substituents were introduced at the amide N-terminus to explore structure-activity relationships (SARs). Series 2 compounds were derived from Cabozantinib by incorporating a rigid pyridine linker via conformational constraint and replacing the terminal phenyl group with bicyclo[1.1.1]pentane (BCP). All target compounds were evaluated for their VEGFR-2 inhibitory activity. Among series 1, compound 20 showed the significant inhibitory activity with an IC₅₀ value of 85.35 nM. Notably, series 2 compounds demonstrated significantly improved potency, with IC

Indexed as

Antiproliferative activityDesign and synthesisInhibitory activityMolecular dockingVEGFR-2 inhibitors

Identifiers

PMID42377824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.